Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced on May 6, 2026, that its compensation committee granted an inducement stock option to Daniel Keefe, the recently-hired Commercial Director for the Western United States. The option to purchase 17,000 shares of common stock was granted on May 5, 2026, as a material inducement for Keefe to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
The option carries an exercise price of $3.20 per share, matching the closing price on the grant date. Vesting occurs one-quarter on the one-year anniversary of the vesting commencement date, with the remaining shares vesting in equal monthly installments over the subsequent three years, contingent on continued employment. The option has a 10-year term and is governed by an inducement stock option agreement.
This grant underscores Aclarion's strategic expansion of its commercial team, driven by increasing demand for its Nociscan platform. Nociscan is a SaaS platform that uses magnetic resonance spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to help physicians noninvasively differentiate between painful and nonpainful discs in the lumbar spine. The company has reported triple-digit growth in utilization, indicating strong market adoption.
Nociscan receives MRS data from MRI machines for each lumbar disc evaluated. In the cloud, the platform extracts and quantifies chemical biomarkers associated with disc pain. These biomarker data are fed into proprietary algorithms to indicate whether a disc may be a source of pain, providing critical insights for optimizing treatment strategies. For more information, visit www.aclarion.com.
The expansion of the commercial team, including the new hire for the Western U.S., reflects Aclarion's commitment to addressing the chronic low back pain market. The company's forward-looking statements, including those regarding demand for Nociscan, are subject to risks and uncertainties detailed in its filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2025. Aclarion undertakes no obligation to update forward-looking statements.
